One company set to benefit from the Cancer Moonshot initiative is Pressure BioSciences (OTCQB: PBIO).
In July, PBIO announced that its Barocycler 2320Extreme system, using its proprietary Pressure Cycling Technology (PCT) platform, will play an important role in a major cancer research study led by ProCan, an Australian research group recently named a Moonshot collaborator by the White House.
A key component to the study's success will be the maximization of the breadth of biomolecular analytes revealed and measured, and the quality and reproducibility of the results generated using the tools chosen by ProCan for both the sample preparation and analytical portions of the study.
When asked to comment on the importance of sample preparation quality, Dr. Isabelle M. Gorrillot, Managing Director of Areon Biosciences, said, “PBIO’s PCT platform may substantially improve research data reliability and efficacy expectations of drug candidates, and in turn significantly mitigate investment risk in their development.”
“By revealing, releasing, and preserving molecular structures that are otherwise likely compromised through current, aggressive mechanical and biochemical treatment of cells in tissue samples, PBIO's PCT platform may significantly increase the speed of targeting and accuracy of drug design and subsequent potency and efficacy data,” continued Gorrillot.
PBIO’s technology represents a true paradigm shift in sample preparation. Current sample preparation methods are mostly mechanical and highly inadequate and have remained unchanged for more than 30 years.
The disruptive potential of PBIO’s platform has been recognized by more than 100 publications and peer reviewed journals from top scientists, validating the advantages of PCT technology.
The technology has been secured through 24 issued patents and even more patents are pending.
To date, more than 275 PCT systems have been installed for more than 160 customers around the globe. Marquee customers of PBIO’s platform include Amgen, Merck, Biogen, Harvard Medical School, Stanford University, the U.S. FDA, Centers for Disease Control, National Institutes of Health and many more.
The revolutionary nature of this technology and its wide application potential represent a multi-billion dollar market opportunity, with an estimated 500,000 scientists in 80,000 research labs globally that could use PCT in their research and drug development.
The potential for PBIO’s reach into this massive market to accelerate got a big boost earlier this year when the company signed a two-year co-marketing agreement with SCIEX, a global leader in mass spectrometry. PCT offers SCIEX a companion solution to their mass spectrometry offerings that improves overall research results.
PBIO’s potential hasn’t gone unnoticed. Earlier this year the company completed a $5 million PIPE offering which was over-subscribed, resulting in a total of $6.3 million in new funding for the company. Investors have more than just future promises to get them excited. PBIO announced revenue increased 42% year-over-year in the second quarter, and the company is guiding for similar growth to continue for the full-year and beyond. The company is also expected to re-list on NASDAQ by end of 2016, which should further increase its visibility on Wall Street, leading to a higher share price and improved valuation.
For the complete article please visit
Red Chip
ABOUT
Dynamic Wealth Research was founded on the principle the world is changing at an ever-increasing pace. The greatest profit opportunities an investor will ever find are from massive, sweeping changes. Dynamic Wealth Research analyzes and closely follows these changes, keeps its readers on the leading edge of them, and shows you how to be best positioned these anxious, interesting, and ultimately profitable times.
